Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience
Osteoprotective therapies have become an essential component in the management of advanced prostate cancer (PC) patients as bone metastases (BMs) have a major impact on morbidity and mortality. Denosumab is a fully humanized antibody targeting the receptor activator of nuclear factor κB ligand (RANK...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-03-01
|
| Series: | Therapeutic Advances in Urology |
| Online Access: | https://doi.org/10.1177/1756287216686018 |